AstraZeneca: Leweichu has been approved in China for the prevention of respiratory syncytial virus infection in infants. AstraZeneca and Sanofi jointly announced on January 2 that the long-acting monoclonal antibody Nirsevimab/Nissevir monoclonal antibody has been officially approved for marketing by the China National Medical Products Administration to prevent lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in newborns and infants. This medication is suitable for newborns and infants who are about to enter or are born during the first RSV infection season. Nisevizumab is expected to be launched in China during the RSV infection season of 2024-2025.